SCHEMBL4589314

SCHEMBL4589314

NCCCC[C@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)CN)C(=O)O.[Mn]

nearest known ligand 0.63

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SLC15A2 Q16348 1/20 0.63
ECE1 P42892 1/20 0.38
FOLH1 Q04609 1/20 0.38
GHSR Q92847 1/20 0.38
SLC6A5 Q9Y345 1/20 0.36
ITGB3 P05106 2/20 0.36
ITGA2B P08514 2/20 0.36
GNPAT O15228 1/20 0.36
ERAP2 Q6P179 1/20 0.36
LNPEP Q9UIQ6 1/20 0.36
CALCRL Q16602 2/20 0.35
NAALAD2 Q9Y3Q0 1/20 0.35
DHFR P00374 1/20 0.35
FPGS Q05932 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4589903 1.00 SLC15A2 (0.63) SLC15A2ECE1FOLH1GHSRSLC6A5
SCHEMBL4589977 1.00 SLC15A2 (0.63) SLC15A2ECE1FOLH1GHSRSLC6A5
SCHEMBL10595108 0.99 SLC15A2 (0.64) SLC15A2ECE1FOLH1GHSRSLC6A5
SCHEMBL259084 0.99 SLC15A2 (0.64) SLC15A2ECE1FOLH1GHSRSLC6A5
SCHEMBL8832939 0.99 SLC15A2 (0.64) SLC15A2ECE1FOLH1GHSRSLC6A5
SCHEMBL259085 0.99 SLC15A2 (0.64) SLC15A2ECE1FOLH1GHSRSLC6A5
SCHEMBL5598418 0.99 SLC15A2 (0.64) SLC15A2ECE1FOLH1GHSRSLC6A5
SCHEMBL2815080 0.98 SLC15A2 (0.63) SLC15A2ECE1FOLH1GHSRSLC6A5
SCHEMBL29767981 0.98 SLC15A2 (0.63) SLC15A2ECE1FOLH1GHSRSLC6A5
SCHEMBL29473319 0.98 SLC15A2 (0.63) SLC15A2ECE1FOLH1GHSRSLC6A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255032-A1 METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN PROCYTE CORPORATION (US) 2008-10-16 US disclosed
US-7384916-B2 Methods and compositions for preventing and treating aging or photodamaged skin PROCYTE CORPORATION (US) 2008-06-10 US disclosed
EP-1866036-A2 METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN PROCYTE CORPORATION (US) 2007-12-19 EP disclosed
EP-1765280-A1 METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING HYPERPIGMENTATION OF SKIN PROCYTE CORPORATION (US) 2007-03-28 EP disclosed
US-20060246029-A1 Methods and compositions for preventing and treating aging or photodamaged skin PROCYTE CORPORATION (US) 2006-11-02 US disclosed
WO-2006101855-A2 METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN PROCYTE CORPORATION (US) 2006-09-28 WO disclosed
US-20060018851-A1 Methods and compositions for preventing and treating hyperpigmentation of skin PROCYTE CORPORATION (US) 2006-01-26 US disclosed
WO-2006004787-A1 METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING HYPERPIGMENTATION OF SKIN PROCYTE CORPORATION (US) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060246029-A1 Methods and compositions for preventing and treating aging or photodamaged skin RBP1, RBP4, SOD1 SLC15A2 2656/4885ECE1 1203/4885FOLH1 2521/4885
US-20060018851-A1 Methods and compositions for preventing and treating hyperpigmentation of skin RBP1, RBP4, MC1R SLC15A2 1582/4885ECE1 1432/4885FOLH1 2500/4885
US-20080255032-A1 METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN RBP1, RBP4, SOD1 SLC15A2 2656/4885ECE1 1203/4885FOLH1 2521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.